Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kamikihito is a traditional Japanese Kampo (herbal) medicine composed of 14 constituent herbs, including Ginseng, Astragalus, and Bupleurum. It is a modification of the Kihito formula, specifically designed to address both physical exhaustion and mental symptoms such as anxiety, insomnia, and neurosis. Manufactured primarily by Tsumura & Co. as TJ-137, it is approved in Japan for conditions including anemia, insomnia, and anxiety. Recent clinical research, such as the KKT-ASTRO trial, has focused on its potential to improve social communication and reduce trait anxiety in adults with Autism Spectrum Disorder (ASD). Its mechanism of action is multi-targeted, involving the modulation of the hypothalamic-pituitary-adrenal (HPA) axis and the GABAergic system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kamikihito.